Comparative Pharmacology
Head-to-head clinical analysis: CLOMIPRAMINE HYDROCHLORIDE versus PRESAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOMIPRAMINE HYDROCHLORIDE versus PRESAMINE.
CLOMIPRAMINE HYDROCHLORIDE vs PRESAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake, with additional anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Predominantly inhibits serotonin reuptake in the presynaptic neuron, increasing serotonin availability in the synaptic cleft. Also inhibits norepinephrine reuptake to a lesser extent.
Oral, initial 25 mg three times daily; increase gradually to 100-250 mg/day in divided doses; maximum 300 mg/day for severe conditions.
100-300 mg/day orally in divided doses, typically starting at 75 mg/day and titrating upward. Maximum dose 300 mg/day.
None Documented
None Documented
Terminal elimination half-life of clomipramine is 19-37 hours (mean ~30 hours); active metabolite desmethylclomipramine has half-life of 54-77 hours. Steady-state achieved within 1-2 weeks.
21 hours (range 16-28 h) for imipramine; active metabolite desipramine ~24 h; clinically, steady-state reached in 5-7 days.
Renal: ~60% (as conjugated metabolites and unchanged drug); Fecal: ~30% (biliary excretion); 2-3% excreted unchanged in urine.
Primarily renal (70% as metabolites, <5% unchanged); biliary/fecal (30%).
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant